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Abstract
Background: General Practitioners {GP} in Sweden prescribe more than 50% of all prescriptions. Scientific
knowledge on the opinions of GPs regarding drug information has been sparse. Such knowledge could be
valuable when designing evidence-based drug information to GPs. GPs’ opinions on public- and industry-provided
drug information are presented in this article.
Methods: A cross-sectional study using a questionnaire was answered by 368 GPs at 97 primary-health care
centres {PHCC}. The centres were invited to participate by eight out of 29 drug and therapeutic committees {DTCs}.
A multilevel model was used to analyse associations between opinions of GPs regarding drug information and
whether the GPs worked in public sector or in a private enterprise, their age, sex, and work experience. PHCC and
geographical area were included as random effects.
Results: About 85% of the GPs perceived they received too much information from the industry, that the quality
of public information was high and useful, and that the main task of public authorities was to increase the GPs’
knowledge of drugs. Female GPs valued information from public authorities to a much greater extent than male
GPs. Out of the GPs, 93% considered the main task of the industry was to promote sales. Differences between the
GPs’ opinions between PHCCs were generally more visible than differences between areas.
Conclusions: Some kind of incentives could be considered for PHCCs that actively reduce drug promotion from
the industry. That female GPs valued information from public authorities to a much greater extent than male GPs
should be taken into consideration when designing evidence-based drug information from public authorities to
make implementation easier.
Background
In Sweden, General Practitioners {GPs} comprise the lar-
gest group of prescribers, writing more than 50% of all
prescriptions [1]. As costs for medication have risen,
there has been an increasing need for finding ways to get
better value for money [2,3]. Focus has increased on evi-
dence-based medicine that refers to the conscientious,
distinct and sensible use of the most reliable and current
knowledge when making decisions affecting individual
patients [4,5]. There has been much debate on how the
pharmaceutical industry influences physicians and assess-
ment agencies [6-9]. Physicians’ attitudes continue to be
positive towards industry-related activities according to
an American hospital study [9]. Published studies with
companies as sponsors are more likely to present results
that favour the company [8] and it has been claimed that
the financial arrangements with industry are well hidden
[7]. The pharmaceutical industry’s financial contribution
to continuing education {CME} of Swedish physicians
has been estimated at one billion Swedish crowns (€104.6
million) [10]. Swedish employers, mainly in the public
sector are said to contribute 67% of the total cost of
CME [11]. However, these figures are based on weak
ground due to trade secrecy, but the best available in
literature.
The development of drug and therapeutic committees
{DTCS} has varied considerably in Europe and has been
particularly extensive in the Nordic countries [12,13]. In
Sweden they began in the 1960s in hospital settings as
collaboration between clinicians, pharmacists and clinical
pharmacologists. Focus was broadened in the 1980s to
increase the commitment of GPs.
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cil is obliged to have at least one DTC whose overall aim
is to promote the rational use of drugs based on evi-
dence-based principles of drug therapy on all levels of
the health care system. This is achieved through the
selection of recommended drugs and support of using
them through education and information in academic
drug detailing, often provided by pharmacists or physi-
cians. The DTCs have worked within multidisciplinary
networks including GPs and other specialized physicians,
district and other specialized nurses, and pharmacists.
Attitudes on new drugs were explored among high and
low prescribing GPs in the UK. Acquired knowledge and
subjective and ideological beliefs were regarded as influ-
ential on prescribing among British GPs [14]. Hospital
physicians, pharmaceutical representatives, prescribing
advisers and cost considerations were in varying degrees
influential on British GPs. There were notable differences
between high and low prescribers of new pharmaceuti-
cals. The impact of cost on prescribing behaviour did not
represent a significant barrier to uptake of new medicines
and seemed to be of lower importance than safety and
efficacy. Limiting the role of the companies could be
necessary to enable cost control [15]. Results from stu-
dies on GPs throughout the world suggest that it is
necessary to limit the role of pharmaceutical companies
in physician training and to emphasize more objective
sources of information [16-21]. The personal information
on drugs might be more important than the message as
was proposed in an Australian qualitative study [22].
Knowledge is sparse of GPs’ opinions and attitudes
regarding drug information services in general, and, in
particular, when contrasting information from indepen-
dent sources with the information originating from the
pharmaceutical industry.
T h ea i mo ft h ep r e s e n ts t u d yw a st oe x p l o r eG P s ’opi-
nions on publicly- and industry-provided drug informa-
tion. This may contribute to identifying target areas for
improving evidence-based drug information to GPs
from the DTCs and the pharmaceutical industry.
Methods
This cross-sectional study was conducted in 2004 using a
questionnaire that was answered by 368 GPs at 97 pri-
mary-health care centres {PHCC} mainly in the southern
part of Sweden, including Stockholm. All 29 Swedish
D T C sw e r ei n v i t e da n de i g h tD T C s ,r e p r e s e n t i n g1 7 3
PHCCs, accepted participation. We chose to invite
through the DTCs as they were in charge of giving public
drug information to GPs. Non-participating DTCs were
occupied with other projects, had lack of informers and
time to participate. The participating DTCs in turn
invited primary health care centres and their GPs to par-
ticipate. Participating PHCCs had 462 GPs in total.
Regional ethical review board approved the study in
2004 (129-04).
Questionnaire
A questionnaire (Table 1) was developed in cooperation
with six experienced colleagues in a network dealing with
medication in the Swedish Association of General Prac-
tice. Seven questions dealt with origin of drug informa-
t i o n ,t h ea m o u n t ,q u a l i t y ,u s e f u l n e s sa n di fs o ,h o ws o o n
the information proved to be useful. One open-ended
question asked for useful examples. Finally GPs were
asked to approve or disapprove to statements whether
the work of industry and public authorities, respectively,
was to i; improve GPs’ knowledge of drugs, ii; to influ-
ence cost of medication (public authorities) or iii; sales of
drugs (industry). All questions (except one) were Likert
scales anchored from 1 to 7. Open-ended questions (item
6) were categorized and the responses in each category
were counted. The first edition was elaborated together
with the above mentioned network of six experienced
colleagues. To increase reliability a first edition of the
questionnaire was tested on the colleagues and revised.
The final version of the questionnaire was sent to each
PHCC director for distribution. Non-responders were
twice reminded with a two-week interval via the director
of the PHCC.
Statistical analysis
For each question, we calculated a dichotomized out-
come variable, which was 1 if the category of the answer
was larger or equal to the median, and 0 if otherwise
[23]. Independent variables were the physician’ss e x ,
work experience, age and whether the physician worked
in the public sector or in private enterprise. These inde-
pendent variables were treated as fixed effects in a multi-
ple logistic regression model. As the physician’sa g ea n d
GP’s experience were strongly correlated they could not
be included in the same model. Thus, each question was
analysed twice, first by age and all other independent
variables except experience, and vice versa.
A multilevel model was used to analyze the correlation
in the opinions of GPs working at the same PHCC or in
an area connected with the same DTC. We included
GPs’ workplace, located within areas belonging to a parti-
cular DTC as random effects in the multilevel logistic
model. For each random effect, the variance between
groups (PHCC or regions) was transformed into an intra-
class correlation coefficient which could be interpreted as
the proportion of variation of the dependent variable that
could be explained by variation in the random effect vari-
able. Two-sided p-values were presented both for fixed
and random effects. Significance was set at 0.05. Data
was entered into the statistical programme Epi-info 3.4.3
(CDC, Atlanta, U.S.A.) which was used for descriptive
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v2.00 (Thousand Oaks, Calif: SAGE; 1999).
Results
Response rates were 28% for the DTCs (8/29), 56% for
the PHCCs (97/173) and 80% for the GPs (368/462),
totally 218 males and 130 females (20 missing values for
sex). Six PHCCs were privately owned and 91 were in
the public sector. Mean experience as a GP was 13.9
years (n = 363, SD 8.6). Mean age was 51 years (SD 7.5)
for male physicians and 49 years (SD 7.2) for female.
There was a mean of 4.8 GPs per PHCC (SD 2.5) with a
range of 1-15 GPs. Six PHCCs had only one GP
employed.
Most GPs, about 85%, thought that the amount of
information from the drug industry was too extensive
(item 2b), that the drug information from public authori-
ties was of high quality and useful (item 3a+4a), that pub-
lic authorities’ main task was to increase the physician’s
knowledge of drugs (item 7a) and that the main purpose
of the industry providing drug information was to pro-
mote sales (item 7d) (Table 1).
In item 1, 4a, 4b and 7a, a consistent finding was
that male GPs were more orientated towards industry-
provided drug information, compared to female GPs
(Table 2). In item 2b, 4b and 7d a consistent finding was
that older GPs and those with longer experience were
more positively orientated towards industry-provided
Table 1 Topics in questionnaire on attitudes to drug information and responses (mean and median) from 368 GPs
Item* N (%)** Mean (SD)
***
Median (IQR)
****
1 Where do you mostly get information about drugs?
(pharmaceutical industry — public authorities)
313
(85.1)
3.7 (2.7) 4.0 (3.0)
2a What is your opinion on the amount of drug information you get from public authorities?
(too scarce — too extensive)
313
(85.1)
3.1 (1.2) 3.0 (2.0)
2b What is your opinion on the amount of information from the pharmaceutical industry?
(too scarce — too extensive)
314
(85.3)
5.6 (1.3) 6.0 (2.0)
3a What is your opinion on the quality of drug information from public authorities?
(very poor — excellent)
313
(85.1)
5.2 (1.4) 6.0 (1.0)
3b What is your opinion on the quality of drug information from the pharmaceutical industry?
(very poor —excellent)
313
(85.1)
3.7 (1.4) 4.0 (2.0)
4a Do you usually find drug information from public authorities useful?
(Not at all — a great deal)
314
(85.3)
5.4 (1.3) 6.0 (1.0)
4b Do you usually find drug information from the pharmaceutical industry useful?
(Not at all — a great deal)
312
(84.8)
3.8 (1.4) 4.0 (2.0)
5a If you usually find drug information from public authorities useful - how soon does it prove to
be useful?
(Later on — immediately)
306
(83.2)
4.5 (1.4) 5.0 (2.0)
5b If you usually find drug information from the pharmaceutical industry useful -how soon does it
prove to be useful?
(later on — immediately)
303
(82.3)
4.3 (1.3) 4.0 (2.0)
6a If you usually find drug information from public authorities useful - please give some examples. ——— ——— ———
6b If you usually find drug information from the pharmaceutical industry useful- please give some
examples.
——— ——— ———
To what extent do you agree with the following four statements? ——— ——— ———
(do not agree at all — agree totally)
7a The main task of the drug information from public authorities is to increase my knowledge of
drugs.
314 (85,
3)
5.7 (1.4) 6.0 (2.0)
7b The main task of the drug information from the pharmaceutical industry is to increase my
knowledge of drugs.
313 (85,
1)
3.5 (1.7) 3.0 (3.0)
7c The main task of the drug information from public authorities is to influence the cost of
medication for providers.
313 (85,
1)
5.0 (1.5) 5.0 (2.0)
7d The main task of the drug information from the pharmaceutical industry is to influence the
company’s sales.
313 (85,
1)
6.2 (1.1) 7.0 (1.0)
*All questions except 6a and 6b were Likert scales anchored from 1 to 7 with 1 representing the alternative seen left in brackets below the item and 7 as the
alternative seen right in brackets below the item. Society = Societal information about drugs from e.g. drug and therapeutic committees, The Medical Products
Agency, The National Board of Health and Welfare, The Swedish Council on Technology Assessment in Health Care, The Swedish Drug Compendium, postal
advertisement, information during lunch, educational events.
**The questions were at most answered by 368 GPs, frequency varying for different questions.
***Mean with standard deviation within parenthesis
****Median with inter quartile range within parenthesis
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with less work experience (Table 2). Older GPs and those
with longer work experience did to a greater extent con-
sider that increasing their knowledge of drugs was a
major task for public authorities (item 7a, Table 2).
Furthermore, GPs with greater work experience consid-
ered to a lesser extent that the aim of public authority
information was to influence the cost of medication to
society (item 7c, Table 2). In item 3b there was a weak
tendency and in item 4b a more consistent finding that
private sector GPs ranked the quality and usefulness of
industry-provided drug information higher as compared
to GPs in the public sector (Table 2). In item 7d GPs in
the public sector to a larger extent considered the main
t a s ko ft h ei n d u s t r yt oi n c r e a s et h e i rs a l e sc o m p a r e dt o
GPs in the private sector (Table 2).
For most items, the random effects describing correla-
tions within PHCCs or regions adhering to the same
DTC were of little importance compared to fixed effects
such as sex, age, work experience and sector (Table 2).
For all questions, we found that the variation in opi-
nions between different PHCCs was larger than between
regions connected to different DTCs, or, in other words,
we observed a relatively high correlation of GPs opi-
nions within the same PHCC, regardless of where they
worked. This was most prominent how the doctors
regarded the usefulness of received information from
the pharmaceutical industry (item 4b). The GPs were
also asked to describe in their own words different
aspects of drug information from public authorities and
from the pharmaceutical industry (item 6a and 6b). The
former was regarded as useful for the GPs in making
Table 2 Questionnaire responses related to sex, age, work experience, sector and geographical area
Fixed effects Random effects
Item
a N
b Sex (female/male)
c Age
cf Work experience
cf Sector (Public/Private)
c PHCC
d Area
e
1 292 1.92 (1.17-3.14)** 1, 01 (0.98-1.04) ——— 1.38 (0.57-3.38) 0.039 0
291 1.97 (1.19-3.26)** ——— 1.02 (0.99-1.06) 1.27 (0.51-3.20) 0.052 0
2a 292 1.64 (0.97-2.79) 1.00 (0.96-1.03) —— 1.06(0.39-2.89) 0.075 0.022
291 1.66 (0.97-2.83) ——— 1.00 (0.97-1.03) 1.07 (0.40-2.87) 0.065 0.026
2b 292 1.35 (0.80-2.26) 0.96 (0.92-0.99)** —— 1.45 (0.54-3.89) 0.082 0.01
291 1.37 (0.81-2.29) ——— 0.98 (0.95-1.00)* 1.50 (0.56-4.00) 0.087 0.001
3a 291 1.46 (0.88-2.43) 0.99 (0.97-1.00) —— 1.67 (0.63-4.43) 0.054 0.031
290 1.49 (0.90-2.48) ——— 0.99 (0.96-1.02) 1.55 (0.58-4.18) 0.060 0.033
3b 291 1.29 (0.78-2.13) 1.03 (1.00-1.07) —— 0.37 (0.13-1.05) 0.092 0
290 1.31 (0.79-2.17) ——— 1.02 (0.99-1.05) 0.36 (0.12-1.04) 0.094 0
4a 292 2.06 (1.24-3.40)** 0.99 (0.97-1.02) —— 1.19 (0.50-2.82) 0.022 0
291 2.07 (1.24-3.44)** ——— 1.00 (0.97-1.03) 1.15 (0.48-2.77) 0.029 0
4b 291 0.55 (0.32-0.94)* 1.04 (1.01-1.08)* —— 0.20 (0.05-0.76)* 0.163* 0.036
290 0.57 (0.33-0.98)* ——— 1.04 (1.00-1.07)** 0.19 (0.05-0.74)* 0.169* 0.034
5a 286 0.82 (0.51-1.33) 1.02 (0.99-1.05) —— 0.95 (0.42-2.16) 0 0
285 0.55 (0.26-1.14) ——— 1.00 (0.95-1.04) 1.00 (0.40-2.49) 0 0
5b 283 1.04 (0.61-1.80) 1.01 (0.98-1.05) —— 0.78 (0.30-2.04) 0 0
282 1.00 (0.58-1.74) ——— 1.00 (0.97-1.03) 0.79 (0.30-2.08) 0 0
7a 292 1.76 (1.02-3.03)* 1.04 (1.00-1.08)* —— 1.27 (0.49-3.24) 0.057 0
291 1.78 (1.03-3.07)* ——— 1.04 (1.01-1.07)** 1.15 (0.46-2.91) 0.047 0
7b 291 1.17 (0.70-1.94) 1.01 (0.98-1.05) —— 0.59 (0.22-1.61) 0.062 0
290 1.20 (0.72-2.01) ——— 1.01 (0.98-1.04) 0.58 (0.21-1.59) 0.065 0
7c 291 1.17 (0.68-2.03) 0.97 (0.93-1.01) —— 0.97 (0.33-2.89) 0.101 0.016
290 1.12 (0.64-1.97) ——— 0.97 (0.94-1.00)* 1.02 (0.33-3.11) 0.112 0.020
7d 291 1.10 (0.68-1.78) 0.96 (0.93-0.99)** ——— 2.70 (1.12-6.49)* 00
290 1.04 (0.64-1.69) ——— 0.97 (0.94-1.00)* 2.80 (1.16-6.75)* 00
*p < 0.05,**p < 0.01.
a Question according to Table 1.
b Number of responders with response for all items included in the regression model.
c Odds ratio (95% confidence interval) — two sided p-value.
First line when age is included as independent variable and second line when working time is included as independent variable.
d Variation among primary health care centres is transformed to intra-class correlation. ICC — One sided p-value for variation.
e Variation among regions is transformed to intra-class correlation. ICC — One side p-value for variation.
f Odds ratio for an increase of one year in age or working time.
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aspects of drug therapy and in providing objective infor-
mation. The latter was regarded as useful in providing
information on new drugs, in making scientific judge-
ments on drugs and providing useful information on
how the patient can use the drugs. To provide informa-
tion of side effects was mentioned as examples of drug
information only by a few GPs for both public authori-
ties and the pharmaceutical industry (Table 3).
Discussion
Main findings
GPs in the study considered that drug promotion from
the industry was too extensive and that drug informa-
tion from public authorities was useful and of good
quality. They also stated that the main task of public
authorities was to promote the GPs knowledge of drugs
and that the industry’s main task was to promote sales.
Male, older, and GPs with longer work experience or
w o r k i n gi nt h ep r i v a t es e c t o rw e r em o r ep o s i t i v e
towards industry-provided information whereas female
GPs to a greater extent valued information from public
authorities.
Strengths and limitations of the study
Sample size or power was not calculated in the study.
For some items the number of answering GPs might be
too small.
Eight out of 29 DTCs in Sweden took part in this study.
The limited number of participating DTCs and the fact
that the northern part of Sweden was represented only
by one geographical area in the study can be regarded as
a limitation. On the other hand 4.2 out of 9.1 million
inhabitants in Sweden lived in the geographical regions
surrounding the participating DTCs. Large and medium-
sized cities as well as rural areas were represented. The
proportions of our study group (37% female and 63%
male) were similar to all GPs in Sweden 2004 and 2005
(38% and 62%)[24]. Despite of the consistency of figures
between the groups we cannot ignore the possibility of
reduced internal validity due to selection bias. Further,
bias due to interest and possibilities to take part in edu-
cation e.g. concerning EBM could also influence the
results. However, the high number of participating GPs
as well as an acceptable response rate could justify the
assumption that the results are representative for Swed-
ish GPs. The proportions of male and female GPs in this
paper correspond to the whole of Sweden and support
the assumption that our sample gives a fairly good repre-
sentation of Swedish GPs.
Comparison with existing literature
Literature on the opinions of GPs’ relations to the phar-
maceutical industry has been published [9,25,26], but
scientific knowledge comparing drug information from,
respectively, public authorities and industry has been
sparse. GPs were accustomed to receiving most of their
information from the pharmaceutical industry. Thus, our
results showing that the greatest part of the GPs drug
information emanates from the industry are not surprising
[26,27]. The response that promotion from the industry
was considered too extensive was also consistent with the
literature [16,18-20]. There are also reasons to believe that
many financial ties between industry and medicine are
hidden [7].
During the last decades critical voices raised against
GPs and other physicians’ dependence on the pharma-
ceutical industry has been augmented. The awareness of
physicians on the effects of the relations has been low
[9,25]. There is evidence that the relations may have
effects on the prescribing, costs and quality [28]. Medical
students in Norway seem to be critical and curious to the
industry and were influenced by their teachers [29] and
today’s students might be important to better align physi-
cian attitudes with current policy trends in future [9].
There are differences between the UK and Greece/
Table 3 Perceived aspects of drug information according to open-ended questionnaire responses (Item 6a and b)
Perceived aspects of drug information Public authorities (item 6a
a) Pharmaceutical industry (Item 6b
a)
n = 205
b n = 186
b
Provide drug information and education
c 5.9% (12) 24% (44)
Provide useful information on how patient can use the drug
c 3.4% (7) 17% (31)
Provide information of side effects
c 6.8% (14) 3.8% (7)
Provide economic aspects of drug therapy
c 16% (33) 1.1% (2)
Provide information on new drugs
c 3.9% (8) 38% (71)
Provide scientific judgement on drugs
c 53% (109) 33% (61)
Provide information from public authorities
c 60% (122) 1.6% (3
d)
Provided information is objective
c 12% (25) 0.54% (1)
a Question according to Table 1
b Number of responders to the item
c Responders wrote freely. The response was then classified into categories and counted. One responder can contribute to more than one alternative
d GPs sometimes perceive that pharmaceutical industry present information from public authorities essential for their product.
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regard to policy trends and costs [15,26]. In the UK GPs
have been influenced by government policies by incen-
tives but there is a risk that unintended consequences
may ensue due to the cost reduction [15]. In Greece/
Cyprus there are no financial incentives to motivate phy-
sicians to prescribe generics and these are not prescribed
by Greek physicians [26].
GPs have a wide domain of practice in combination with
lack of time [30]. This might imply that GPs could be
more vulnerable to exposure to pharmaceutical advertise-
ments than other physicians. The amount of new informa-
tion has been extensive and keeping up to date with best
evidence in health is challenging [31]. To be able to main-
tain a critical appraisal of new medical concepts, e.g. as
prehypertension was recognized as diagnose [32], it is
important to allow time for continuing education, reading
and reflection based on reliable sources [26,27,33]. An
informer giving evidence-based knowledge adjusted to the
week-day of GPs could perhaps be one appropriate means
for this. An American survey showed that significant atti-
tude shifts were seen among physicians concerning per-
ceptions about industry after information on their working
methods [33].
A consistent and new finding was that male GPs were
more orientated towards industry-provided drug infor-
mation compared to female GPs. This finding needs
further investigation but earlier findings concerning phy-
sician gender differences showing that female physicians
were more involved and had longer visits [34] as well as
differences in prescription patterns [35] indicate the exis-
tence of gender differences in this field.
Concerning the opinions on both public authority and
industry-supplied drug information services, the role of
the information provider, as an important link between
the public authorities or the industry and the GP, must be
put forward even if the literatu r ei ss p a r s e[ 2 2 ] .P u b l i c -
authority providers in Sweden are often GPs or pharma-
cists and usually well known and accepted by the GPs,
traditionally not putting focus on GPs as customers.
An Australian study on hypertension advertisements
implied that the industry lacked elements important for
cost-effective care consistent with evidence-based guide-
lines [36]. In another study exposure to pharmaceutical
information was associated with either no effect or
adverse effect on prescribing [28]. This implies that phy-
sicians could be seen as customers representing medical
care in relation to the industry.
Changing medical culture and physician education is
an important field to be improved as many physicians
still hold positive attitudes toward marketing-oriented
activities [9]. The positive attitudes in this study could
perhaps partly be explained by some GPs’ appreciation
of the usefulness of the information provided by the
industry on how the patient could use drugs. This was
mentioned only by a few GPs as examples of useful
information from the public authorities.
From the mid 90 s, the relations between the public
health care and GPs on the one hand and the industry
on the other became chillier in Sweden. There has long
been a largely ignored ethical agreement between health
care and industry concerning education, information
and clinical trials. A debate concerning regions’ task of
taking economic responsibility for drugs, instead of the
state, was accelerating. In due course this led to a new
and more efficient agreement which was initiated in
2004 [37]. Our finding that older GPs and those with
m o r ey e a r so fe x p e r i e n c ew e r em o r ep o s i t i v et o w a r d s
industry-provided promotion might be explained by
their experience from a closer relationship that earlier
was accepted. These contacts are still accepted in other
countries [9,26] and perhaps attitudes of younger GPs in
Sweden are more like those in the UK [15]. That older
and more experienced GPs also considered that increas-
ing their knowledge was a major task for public authori-
ties could perhaps be explained by their knowledge that
the industry is prone to sell their products but not to
give a wider spectrum of information. An Australian
print advertisement study found that advertisements
p r o v i d es o m eb u tn o ta l lk e ym e s s a g e sf o rag u i d e - l i n e
concordant care [36]. GPs working in private enterprise
were more positive towards the industry in this study.
This might be a reflection of entrepreneurs having a
more sceptical approach to public authorities.
There were greater differences in use of industry-pro-
vided information betweenP H C C s ,t h a nb e t w e e ng e o -
graphical areas. Since the new agreement between
regions and the pharmaceutical industry was settled
[37], the tradition of seeing pharmaceutical representa-
tives at lunchtime has been reduced at most but not at
all PHCCs. This might explain the high ICC for PHCC
in item 4b (Table II). Leadership forming policies at the
centres could also have other impacts on attitudes [38]
as could work conditions and culture among GPs and
other staff.
Conclusions
As Swedish GPs considered drug promotion from the
industry to be too extensive some kind of incentives
could be considered for PHCCs that actively reduce
drug promotion from the industry.
Female GPs valued information from public authori-
ties to a much greater extent than male GPs and this
difference should be taken into consideration when
designing evidence-based drug information from public
authorities to make implementation easier.
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